News | March 20, 2008

Parachute Heart Pump Implanted in First U.S. Patient

March 21, 2008 – A central Ohio man has become the first person in the U.S., and only the 16th worldwide, to receive a heart implant called the CardioKinetix VPD Implant System designed to improve the heart’s pumping action and help manage congestive heart failure symptoms.

The procedure was performed at The Ohio State University Medical Center. The center is dedicated to heart failure and interventional research and is one of five academic medical centers participating in an FDA-approved safety and feasibility trial called U.S. PARACHUTE Trial. The device, CardioKinetix VPD Implant System, has FDA Investigational Exemption (IDE) approval for investigational use only and was developed by CardioKinetix Inc., Redwood City, CA.

Congestive heart failure occurs when a patient’s heart is not pumping blood efficiently, most often due to a weak heart muscle damaged by a prior heart attack. As part of a multicenter trial, the study device, which looks like a parachute turned inside out, is placed in the damaged portion of the pumping chamber of the heart and essentially partitions off the inefficient portion of the weakened heart chamber.

An advantage of the device is that it can be implanted via a small incision in the patient’s leg artery without the need for general anesthesia or open heart surgery, allowing for faster recovery time. Most patients, including the patient implanted at Ohio State, are discharged the day after the procedure.

“The concept of this device is to decrease the size of an abnormally enlarged heart with the hope of improving the patient’s symptoms such as shortness of breath, fatigue and swelling,” said Ernest Mazzaferri, Jr., M.D., an interventional cardiologist at Ohio State ’s Richard M. Ross Heart Hospital, who implanted the device March 11.

“This device has the potential to help many of these millions of heart failure patients,” said William T. Abraham, M.D., director of cardiovascular medicine at The Ohio State University Medical Center and national principal investigator for the trial.

The study is funded by CardioKinetix, Inc.

For more information: and

Related Content

Sponsored Content | Videos | Cardiovascular Ultrasound| July 19, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD)| June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Italian Boy Becomes Youngest Patient Bridged to Transplant With SynCardia Total Artificial Heart

Andrei, 12, is the world’s youngest patient to be bridged to transplant with the SynCardia Total Artificial Heart. He is pictured after his heart transplant with his surgeon, Antonio Amodeo, M.D., at Bambino Gesù Children’s Hospital in Rome, Italy. Photo courtesy of Business Wire.

News | Congenital Heart| June 22, 2017
A 12-year-old boy at Bambino Gesù Children’s Hospital in Rome, Italy, has become the world’s youngest patient to be...
Abiomed Impella CP pVAD, third-generation CP
Technology | Hemodynamic Support Devices| June 12, 2017
June 12, 2017 — Abiomed Inc.
tandemLife Tandemheart priming tray cleared by FDA
Technology | Hemodynamic Support Devices| June 12, 2017
June 12, 2017 — TandemLife began its commercial launch of the TandemLife Priming Tray, a new product designed to simp
Sponsored Content | Videos | Cardiovascular Ultrasound| May 26, 2017
This video, provided in partnership with the American Society of Echocardiography (ASE), is titled "Intraoperative Tr
Impella CP study to investigate door to left ventricular unloading time
News | May 09, 2017
May 9, 2017 — The first patient has been enrolled in the U.S.
Heartware HVAD recall for its ventricular assist device from Medtronic
Feature | Ventricular Assist Devices (VAD)| May 05, 2017
May 5, 2017 — Medtronic Mechanical Circulatory Support is expanding its recall of its HeartWare Ventricular Assist De
the Impella pVAD improves survival, mortality in AMI heart attack with cardiogenic shock

Early use of the Impella percutaneous ventricular assist device prior to angioplasty may significantly improve survival for patients in cardiogenic shock.

Feature | Hemodynamic Support Devices| April 28, 2017 | Dave Fornell
Recent clinical study data presented at the American College of Cardiology (ACC) 2017 meeting show new treatment prot
Sponsored Content | Videos | Ventricular Assist Devices (VAD)| April 14, 2017
A discussion with William O'Neill, M.D., FACC, FSCAI, medical director of the Center for Structural Heart Disease at
Overlay Init